EP4050004A4 - Morpholine bicyclique à gauche et son sel, son procédé de préparation, composition pharmaceutique et application - Google Patents
Morpholine bicyclique à gauche et son sel, son procédé de préparation, composition pharmaceutique et application Download PDFInfo
- Publication number
- EP4050004A4 EP4050004A4 EP20892802.8A EP20892802A EP4050004A4 EP 4050004 A4 EP4050004 A4 EP 4050004A4 EP 20892802 A EP20892802 A EP 20892802A EP 4050004 A4 EP4050004 A4 EP 4050004A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- handed
- salt
- preparation
- application
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 title 2
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- 150000003839 salts Chemical class 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
- C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
- C07D407/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
- C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
- C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
- C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
- C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
- C07D317/64—Oxygen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/07—Optical isomers
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201911190936.4A CN112851626B (zh) | 2019-11-28 | 2019-11-28 | 一类左旋双环吗啉，其制备方法、药物组合物和应用 |
| PCT/CN2020/115410 WO2021103749A1 (fr) | 2019-11-28 | 2020-09-15 | Morpholine bicyclique à gauche et son sel, son procédé de préparation, composition pharmaceutique et application |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| EP4050004A1 EP4050004A1 (fr) | 2022-08-31 |
| EP4050004A4 true EP4050004A4 (fr) | 2023-12-06 |
Family
ID=75995502
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EP20892802.8A Pending EP4050004A4 (fr) | 2019-11-28 | 2020-09-15 | Morpholine bicyclique à gauche et son sel, son procédé de préparation, composition pharmaceutique et application |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230002343A1 (fr) |
| EP (1) | EP4050004A4 (fr) |
| JP (1) | JP2023508844A (fr) |
| KR (1) | KR20220107036A (fr) |
| CN (1) | CN112851626B (fr) |
| AU (1) | AU2020390812A1 (fr) |
| WO (1) | WO2021103749A1 (fr) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN114652692B (zh) * | 2022-04-28 | 2023-09-01 | 长春钻智制药有限公司 | 一种治疗肝病的药物缓释片及其制备方法和用途 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1275961C (zh) * | 2002-12-12 | 2006-09-20 | 中国医学科学院药物研究所 | 光活双环醇及其制备方法和其药物组合物与用途 |
| CN100404527C (zh) * | 2006-03-07 | 2008-07-23 | 河南省科学院质量检验与分析测试研究中心 | 手性4,4＇-二甲氧基-5,6,5＇,6＇-二次甲二氧基联苯-2,2＇-二甲酸衍生物及其制备方法 |
| CN107488162B (zh) * | 2015-10-19 | 2020-09-18 | 中国医学科学院药物研究所 | 一类双环醇类衍生物及其制备和应用 |
-
2019
- 2019-11-28 CN CN201911190936.4A patent/CN112851626B/zh active Active
-
2020
- 2020-09-15 US US17/775,402 patent/US20230002343A1/en active Pending
- 2020-09-15 EP EP20892802.8A patent/EP4050004A4/fr active Pending
- 2020-09-15 WO PCT/CN2020/115410 patent/WO2021103749A1/fr unknown
- 2020-09-15 KR KR1020227022153A patent/KR20220107036A/ko unknown
- 2020-09-15 AU AU2020390812A patent/AU2020390812A1/en active Pending
- 2020-09-15 JP JP2022532069A patent/JP2023508844A/ja active Pending
Non-Patent Citations (1)
| Title |
|---|
| No further relevant documents disclosed * |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2021103749A1 (fr) | 2021-06-03 |
| EP4050004A1 (fr) | 2022-08-31 |
| AU2020390812A1 (en) | 2022-06-30 |
| JP2023508844A (ja) | 2023-03-06 |
| CN112851626A (zh) | 2021-05-28 |
| US20230002343A1 (en) | 2023-01-05 |
| KR20220107036A (ko) | 2022-08-01 |
| CN112851626B (zh) | 2022-09-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3875458A4 (fr) | Composé de type diphényle, son intermédiaire, son procédé de préparation, sa composition pharmaceutique et ses applications | |
| EP3835296A4 (fr) | Composé de cétoamide et procédé de préparation, composition pharmaceutique et utilisation associée | |
| EP3862348A4 (fr) | Composé d'isoindoline, procédé de préparation, composition pharmaceutique et utilisation associée | |
| EP3971187A4 (fr) | Inhibiteur contenant un dérivé bicyclique, son procédé de préparation et son utilisation | |
| EP3744316A4 (fr) | Composition pharmaceutique ophtalmique, son procédé de préparation et son application | |
| EP4079734A4 (fr) | Dérivé de triazolopyridazine, son procédé de préparation, composition pharmaceutique associée et utilisation correspondante | |
| EP3785713A4 (fr) | Sel de cetagliptin, sa méthode de préparation, composition pharmaceutique et son utilisation | |
| EP3670511A4 (fr) | Composé de tétrahydroprotoberbérine, son procédé de préparation, ses utilisations et composition pharmaceutique | |
| EP3647313A4 (fr) | Composé aryléther substitué, son procédé de préparation, composition pharmaceutique et son utilisation | |
| EP3750886A4 (fr) | Composé de tétrahydroisoquinoléine, son procédé de préparation, composition pharmaceutique le contenant et utilisation associée | |
| EP3828169A4 (fr) | Composé dication, son procédé de préparation et son utilisation | |
| IL285378A (en) | A heterocyclic compound, a medical preparation containing it, a method for its preparation, and its use | |
| EP4053154A4 (fr) | Kératine bd-10, son procédé de préparation, et composition pharmaceutique de celle-ci, et son utilisation | |
| EP4001260A4 (fr) | Dérivé de dibromobenzyle, stéréoisomère ou sel de celui-ci, et son procédé de préparation et son utilisation | |
| EP3865488A4 (fr) | Composé macrocyclique servant d'inhibiteur de cdk, son procédé de préparation et son utilisation en médecine | |
| EP3492461A4 (fr) | Composé aromatique hétérocyclique azoté, son procédé de préparation, composition pharmaceutique à base de celui-ci et son application | |
| EP3777862A4 (fr) | Composition de méloxicam, sa préparation et son procédé de préparation et son utilisation | |
| EP3760191A4 (fr) | Composition pharmaceutique, procédé de préparation et utilisation de cette dernière | |
| EP3747863A4 (fr) | Dérivé de probucol, son procédé de préparation et son utilisation | |
| EP4059501A4 (fr) | Composition pharmaceutique de crotonamide substitué et son procédé de préparation | |
| EP3608312A4 (fr) | Composés de sel d'imidazole substitués, leur procédé de préparation, composition pharmaceutique et applications associées | |
| EP4063453A4 (fr) | Composition de polypropylène, son procédé de préparation et son utilisation | |
| EP4050004A4 (fr) | Morpholine bicyclique à gauche et son sel, son procédé de préparation, composition pharmaceutique et application | |
| EP3858812A4 (fr) | Inhibiteur de mdm2, son procédé de préparation, composition pharmaceutique associée et utilisation correspondante | |
| EP3898582A4 (fr) | Nouveaux dérivés d'acide salicylique, sel pharmaceutiquement acceptable de ceux-ci, composition associée et procédé d'utilisation correspondant |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE |
|
| PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
| STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE |
|
| 17P | Request for examination filed |
Effective date: 20220526 |
|
| AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
|
| DAV | Request for validation of the european patent (deleted) | ||
| DAX | Request for extension of the european patent (deleted) | ||
| A4 | Supplementary search report drawn up and despatched |
Effective date: 20231107 |
|
| RIC1 | Information provided on ipc code assigned before grant |
Ipc: A61K 31/5377 20060101ALI20231031BHEP Ipc: A61P 37/02 20060101ALI20231031BHEP Ipc: A61P 31/20 20060101ALI20231031BHEP Ipc: A61P 31/14 20060101ALI20231031BHEP Ipc: A61P 1/16 20060101ALI20231031BHEP Ipc: C07D 317/68 20060101AFI20231031BHEP |